Dysport® Pediatric Lower Limb Spasticity Follow-on Study

Inclusion Criteria: Subjects were eligible for participation in the study if they met the following criteria:

1. Completion of the double blind study (Study 141) up to the Week 12, Week 16, Week 22or Week 28 follow up visit.
2. Without any major protocol deviations and/or any ongoing adverse events (AEs), eitherof which, in the opinion of the Investigator would pose an unacceptable risk to thesubject were he/she to continue receiving treatment in this open label extensionstudy.
3. Written informed consent obtained from the child's parent(s)/guardian(s) for thisstudy, and assent from the child when and where applicable.

Exclusion Criteria: Subjects were excluded from entering the study for the following reasons:

1. Major limitation in the passive range of motion at the ankle, as defined by maximumankle dorsiflexion measured by the angle of arrest (XV1) at slow speed <80° (TS angle)in the most affected leg to be injected.
2. Unwillingness or inability to comply with the protocol.
3. Current need for surgery for spasticity of the gastrocnemius-soleus complex (GSC)and/or hamstring muscles (and/or tendons) in the most affected leg to be injected.
4. Treatment with any drug that interferes either directly or indirectly withneuromuscular function (e.g. aminoglycoside antibiotics) or neuroblocking agents usedduring surgery (e.g. curare) within the last 30 days prior to study medication or aplanned treatment with such drugs.
5. Be pregnant and/or lactating.
6. Female subjects, not willing to use contraceptive measures throughout the course ofthe study if post pubertal and sexually active.
7. An infection at the injection site(s).
8. Planned treatment with any new investigational drug or device during the study period.